Summary of clinical investigations in α-particle RIT of NHL
| Radionucleotide-labeled antibody | Main finding | Reference |
|---|---|---|
| 227Th-3,2-3,2-hydroxypyridinone (HOPO)-epratuzumab (anti-CD22, BAY 1862864) | BAY 1862864 (up to 6.1 MBq) showed safety and tolerability in 21 relapsed/refractory low- and high-grade NHL patients in a first-in-human dose-escalation phase I study. | [50] |